IDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight

IDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings and revenue beat, an upgraded 2026 outlook, and a fresh expansion of its Fecal Dx parasite testing platform.

The recent earnings beat, upgraded 2026 outlook, and broader Fecal Dx parasite menu come after a period where the share price has eased, with the 90 day share price return down 7.18% and the year to date share price return down 15.71%, even as the 1 year total shareholder return is 8.14%, which hints at longer term holders still being in positive territory.

If this kind of diagnostics story interests you, it can be useful to see what else is shaping healthcare and pet care, including companies using AI in medicine, through our 40 healthcare AI stocks.

The stock has eased in recent months, even though earnings, revenue, and guidance have all exceeded expectations. Are you looking at an underappreciated diagnostics leader, or has the market already fully reflected its growth story in the price?

Most Popular Narrative: 25% Undervalued

The most followed narrative sees IDEXX Laboratories trading below an implied fair value of $750.23 compared with the last close of $564.74, and ties that gap to recurring diagnostics growth and margin assumptions.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Want to understand why this narrative treats a premium P/E and high margins as achievable, not aspirational? The entire case leans on recurring diagnostics, richer software revenue, and a specific glide path for earnings and share count. Curious which assumptions really carry the $750.23 fair value and how much growth is baked into that gap versus today’s price?

Result: Fair Value of $750.23 (UNDERVALUED)

However, this hinges on clinic visit trends and international adoption not slowing more than expected, and on competitors not chipping away at pricing power or recurring diagnostics demand.

Another Angle On Price: Earnings Multiple Looks Stretched

That 25% undervalued fair value hinges on long term cash flows, but the current P/E of 40.7x tells a different story. It sits well above the peer average of 26.4x and a fair ratio of 28.5x, which points to meaningful valuation risk if sentiment or growth expectations cool from here.

For a closer look at how this valuation gap could matter for your own expectations, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to move quickly and test the numbers yourself, then weigh the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If IDEXX has sharpened your focus, do not stop here. Broaden your watchlist with curated stock ideas that could suit different risk levels and return goals.

• Target value opportunities by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that may sit below their implied worth.
• Strengthen your defensive side by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair healthy finances with underlying business resilience.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems before others spot them and pricing expectations shift.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.